A lentivirus-vectored feline erythropoietin gene therapy strategy in tissue culture and rodent models for the potential treatment of chronic renal disease-associated anemia
American Journal of Veterinary Research · 2024
DOI: 10.2460/ajvr.23.12.0280 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Veterinary Research, 2024. Verfasst von Sarah E Cook und 6 weiteren Autor:innen. Beteiligte Einrichtung: SpecialtyVETPATH, Seattle, WA. Hauptthemen laut MEDLINE: Erythropoietin, Genetic Therapy, Lentivirus, Anemia. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVE The aim of this study was to assess the efficacy and safety of a third-generation lentivirus-based vector encoding the feline erythropoietin (EPO) (feEPO) gene in vitro and in rodent models in vivo. This vector incorporates a genetic mechanism to facilitate the termination of the therapeutic effect in the event of supraphysiologic polycythemia, the herpes simplex virus thymidine kinase (HSV-TK) “suicide gene.” ANIMALS CFRK cells and replication-defective lentiviral vectors encoding feEPO were used for in vitro experiments. Eight Fischer rats were enrolled in the pilot in vivo study, 24 EPO-deficient mice were used in the initial mouse study, and 15 EPO-deficient mice were enrolled in the final mouse study. METHODS Efficacy of a third-generation lentivirus encoding feEPO was determined in vitro using western blot assays. Subsequently, in a series of rodent experiments, animals were administered the viral vector in progressively increasing inoculation doses with serial measurements of blood packed cell volume (PCV) over time. RESULTS We documented production of feEPO protein in transduced CRFK cells with subsequent cessation of production when treated with the HSV-TK substrate ganciclovir. In vivo, we demonstrated variably persistent elevated PCV values in treated rats and mice with eventual return to baseline values over time. CLINICAL RELEVANCE These results provide justification for a lentiviral gene therapy approach to the treatment of nonregenerative anemia associated with chronic renal disease in cats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SpecialtyVETPATH, Seattle, WA.
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California-Davis, Davis, CA.
- National Institute of Allergy and Infectious Disease, Hamilton, MT.
- Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS.
Zitieren
APA
Cook, S. E., Castillo, D., Wolf, T., Hillman, C., Bauer, K., Williams, S., & Murphy, B. G. (2024). A lentivirus-vectored feline erythropoietin gene therapy strategy in tissue culture and rodent models for the potential treatment of chronic renal disease-associated anemia. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.23.12.0280
Vancouver
Cook SE, Castillo D, Wolf T, Hillman C, Bauer K, Williams S, et al. A lentivirus-vectored feline erythropoietin gene therapy strategy in tissue culture and rodent models for the potential treatment of chronic renal disease-associated anemia. American Journal of Veterinary Research. 2024. doi:10.2460/ajvr.23.12.0280
BibTeX
@article{Cook2024,
author = {Cook, Sarah E and Castillo, Diego and Wolf, Tatiana and Hillman, Chadwick and Bauer, Katherine and Williams, Sonyia and Murphy, Brian G},
title = {A lentivirus-vectored feline erythropoietin gene therapy strategy in tissue culture and rodent models for the potential treatment of chronic renal disease-associated anemia},
journal = {American Journal of Veterinary Research},
year = {2024},
doi = {10.2460/ajvr.23.12.0280}
}
EUVIMED